Edition:
United Kingdom

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

16.12USD
9:00pm BST
Change (% chg)

$0.37 (+2.35%)
Prev Close
$15.75
Open
$15.77
Day's High
$16.26
Day's Low
$15.38
Volume
4,211
Avg. Vol
10,254
52-wk High
$27.83
52-wk Low
$10.50

Select another date:

Wed, Apr 4 2018

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies

* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Arsanis Granted Key Patents For ASN100 Covering Cross-Neutralizing S. Aureus Toxin Antibodies

* ARSANIS GRANTED KEY PATENTS FOR ASN100 COVERING CROSS-NEUTRALIZING S. AUREUS TOXIN ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Arsanis Reports Q4 Net Loss $1.68 Per Share

* ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017

BRIEF-Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing

* ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING Source text (http://bit.ly/2AvvJ48) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20

* NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING Source text : [ID:http://bit.ly/2ncluP0] Further company coverage:

Select another date: